Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Failure to bictegravir and development of resistance mutations in an antiretroviral-experienced patient.

Antiviral research - 1 Jul 2020

Lozano Ana Belén, Chueca Natalia, de Salazar Adolfo, Fernández-Fuertes Elisa, Collado Antonio, Fernández Juan Manuel, Álvarez Marta, García Federico

Abstract excerpt

We present here one of the first cases of virological failure during treatment with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF). On March 2019, an antiretroviral-experienced HIV-infected patient was admitted to hospital because of cerebral toxoplasmosis. After undergoing treatment with sulfadiazine-pyrimethamine for two weeks, the patient initiated a BIC/FTC/TAF treatment, with 6.01 HIV RNA Log...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Amides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Emtricitabine

Share to Heterocyclic Compounds, 3-Ring

Share to Heterocyclic Compounds, 4 or More Rings

Share to Pyridones

Share to Tenofovir

Share to Treatment Failure

Source

Identifiers

PMID: 31982483
DOI: 10.1016/j.antiviral.2020.104717

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Failure to bictegravir and development of resistance mutations in an antiretroviral-experienced patient.PMID 31982483Read ↗

Virological failure and resistance emergence during treatment with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir/lamivudine in people living with HIV without prior resistance mutations: a real-world study.Semantic proximity Read ↗

Integrase strand transfer inhibitor resistance mediated by R263K plus E157Q in a patient with HIV infection treated with bictegravir/tenofovir alafenamide/emtricitabine: case report and review of the literatureSemantic proximity Read ↗

Factors associated with virological failure in people with HIV treated with bictegravir/emtricitabine/tenofovir alafenamide. Impact of pre-existing mutations and risk of resistance emergence. ANRS-CO3-AquiVIH-NA cohort.Semantic proximity Read ↗

Bictegravir/emtricitabine/tenofovir alafenamide in patients with genotypic NRTI resistance.Semantic proximity Read ↗

Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI ResistanceSemantic proximity Read ↗

Bictegravir/emtricitabine/tenofovir alafenamide in viremic people with HIV harbouring nucleos(t)ide reverse transcriptase inhibitor resistance-associated mutations.Semantic proximity Read ↗

Rare emergence of drug resistance in HIV-1 treatment-naïve patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide for 144 weeks.Semantic proximity Read ↗

Virological failure to raltegravir in Spain: incidence, prevalence and clinical consequences.Semantic proximity Read ↗

Emergence of Resistance to Integrase Strand Transfer Inhibitors during Dolutegravir Containing Triple-Therapy in a Treatment-Experienced Patient with Pre-Existing M184V/I Mutation.Semantic proximity Read ↗

Resistance mutations before and after tenofovir regimen failure in HIV-1 infected patients.Semantic proximity Read ↗

Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.Semantic proximity Read ↗

Two Cases of Viral Re-suppression After M184V + R263K Selection on Dolutegravir/Lamivudine Without Treatment Modification.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.